{"filings":[{"id":1027480,"accession_number":"0001628280-26-042846","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2026-06-12T20:10:37+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CAMP4 stockholders approve 2024 Plan amendment; Board adopts 2026 Inducement Plan (500K shares) for new hires","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2024 Equity Incentive Plan to include pre-funded warrants in evergreen share calculation.","Board adopted 2026 Inducement Plan reserving 500,000 shares of common stock for inducement grants to new employees without stockholder approval.","Annual meeting results: re-elected directors Holtzman, Stewart, Young; ratified Ernst & Young as auditor for FY2026.","Plan amendment and inducement plan both effective as of June 10, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":78482,"accession_number":"0001736730-26-000033","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2026-05-14T13:01:44+00:00","items":["7.01","9.01"],"status":"ready","headline":"CAMP4 Therapeutics reports preclinical data showing CMP-002 improves seizure threshold in SYNGAP1 model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CMP-002 produced statistically significant improvement in seizure threshold and severity in SYNGAP1 haploinsufficient mice.","Data presented at TIDES conference on May 14, 2026; builds on prior motor/behavioral benefit evidence.","Company plans to advance CMP-002 into a Phase 1/2 clinical trial in SYNGAP1-related disorder in H2 2026.","Lead candidate CMP-002 is an antisense oligonucleotide targeting regulatory RNA to upregulate SYNGAP1 protein.","Study used PTZ-induced seizure model; CMP-002 conferred resistance to tonic-clonic seizures and reduced severity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95083,"accession_number":"0001628280-26-032096","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CAMP4 Therapeutics reports Q1 net loss $18.3M; files first CMP-002 regulatory submission in Australia","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $99.2M as of 3/31/26, down from $109.5M; runway expected into 2028.","Net loss $18.3M vs $12.4M YoY, including $6.2M non-cash loss on derivative tranche liability.","Submitted first regulatory filing for CMP-002 (SYNGAP1) in Australia; global Phase 1/2 trial anticipated in 2H 2026.","EMA granted orphan designation for CMP-002; FDA ODD application pending.","Appointed Michael MacLean to Board of Directors."],"consensus_eps_estimate":-0.2142,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":1294000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107900,"accession_number":"0001736730-26-000021","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CAMP4 appoints Michael MacLean to Board, effective April 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael MacLean, former CFO of Avidity Biosciences, joins as Class III director; board expands to 9 members.","MacLean appointed to Audit and Compensation Committees; will receive standard director compensation.","Board amended non-employee director compensation policy: new directors granted options for 56,000 shares vesting over 3 years.","MacLean brings over 35 years of financial leadership in biotech, including roles at Avidity, Akcea, PureTech, and Biogen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107899,"accession_number":"0001736730-26-000015","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CAMP4 FY2025 net loss $80.4M; cash runway into 2028, GSK deal, SYNGAP1 progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $80.4M in FY2025 vs $51.8M in FY2024, driven by $29.8M non-cash loss on derivative tranche liability.","Cash and equivalents $109.5M (Dec 31, 2025), up from $64.0M; cash runway extended into 2028.","GSK collaboration: $17.5M upfront, up to $440M in milestones plus tiered royalties for ASO candidates in neurodegenerative and kidney diseases.","GLP tox studies for CMP-002 ongoing; global Phase 1/2 trial in SYNGAP1 patients expected as early as H2 2026.","Paused development of CMP-001 and exploring partnership opportunities for that program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107898,"accession_number":"0001736730-26-000004","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CAMP4 Therapeutics updates corporate presentation; no specific material changes disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished an updated corporate presentation as Exhibit 99.1.","Presentation is available on the Investors section of the company's website.","No financial results, pipeline milestones, or guidance changes announced in the filing.","The 8-K is a routine Regulation FD disclosure with no new material information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124312,"accession_number":"0001736730-25-000116","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"CAMP4 Therapeutics moves to larger Watertown lab; terminates Cambridge lease early with ~$2.1M fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New 44,000 sq ft Watertown lease (100 Talcott Ave) through June 2030; base rent $40/sq ft with 3% annual escalations.","Cambridge lease (30,760 sq ft, One Kendall Square) terminated 30 days after Watertown commencement; rent abated from Oct 1, 2025.","Lease modification fee of ~$2.1M paid to landlord over additional rent abatement period.","Watertown rent commencement 120 days after target commencement (~180 days from Dec 22, 2025); further abated for 14 months.","Five-year extension option at market rent ≥$85/sq ft."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124311,"accession_number":"0001736730-25-000111","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"CAMP4 enters collaboration with GSK for ASO therapeutics; $17.5M upfront, up to $440M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Collaboration with GSK to discover ASO therapeutics for neurodegenerative and kidney diseases using CAMP4's RAP Platform.","CAMP4 receives $17.5M upfront; eligible for up to $440M in milestone payments plus tiered royalties.","CAMP4 performs research to identify and deliver lead ASO series; GSK responsible for development and commercialization.","Tiered royalties on annual net sales range from low- to mid-single digits; royalty term per product defined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124310,"accession_number":"0001628280-25-058009","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CAMP4 Therapeutics prices 5M share offering at $6.00, expects $28M net proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CAMP4 Therapeutics priced public offering of 5,000,000 shares of common stock at $6.00 per share.","Net proceeds expected to be approximately $28.0 million after underwriting discounts and expenses.","Underwriting agreement with Leerink Partners LLC; closing expected on or about December 19, 2025.","Executive officers, directors, and certain stockholders agreed to a 60-day lock-up on share sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124309,"accession_number":"0001736730-25-000092","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CAMP4 Q3 net loss $15.1M, cash $75.3M; advances CMP-002 with up to $100M placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and marketable securities $75.3M at Sept 30, up from $39.1M at June 30.","Private placement initially closed $50M with potential proceeds up to $100M to fund CMP-002.","Initiated GLP toxicology studies for CMP-002; Phase 1/2 trial expected as early as H2 2026.","Strategic decision to pursue partnership for further development of CMP-001 (urea cycle disorders).","Net loss $15.1M for Q3 2025 vs $13.5M for Q3 2024; R&D expenses $9.4M, G&A $4.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":3150000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124308,"accession_number":"0001736730-25-000074","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CAMP4 initiates GLP toxicology studies for CMP-SYNGAP-01; Phase 1/2 target H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated GLP toxicology studies for CMP-SYNGAP-01, a regulatory RNA-targeting therapeutic for SYNGAP1-related disorders.","Positive preclinical data: restored SYNGAP1 protein in mouse model, increased protein in brain regions of non-human primates.","Planned CTA submission could enable first-in-human Phase 1/2 trial as early as H2 2026.","No FDA-approved disease-modifying therapies exist for SYNGAP1-related disorders; current treatment limited to supportive care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140987,"accession_number":"0001736730-25-000072","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"CAMP4 Therapeutics announces up to $100M private placement and board changes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial closing raises $50M from 26.7M shares at $1.53/share, pre-funded warrants, and management shares; total upfront proceeds ~$50M.","Second closing of up to $50M contingent on regulatory clearance for SYNGAP1 trial and stock price milestone or waiver.","Directors James Boylan, Ravi Thadhani, and Paula Ragan resigned; Doug Williams appointed Board Chair.","Daniel Tardiff elevated to Chief Scientific Officer effective October 1, 2025.","Financing led by Coastlands Capital with Janus Henderson, Balyasny, Vivo Capital, 5AM Ventures and others."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140986,"accession_number":"0001736730-25-000068","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CAMP4 reports Q2 net loss of $12.6M; cash $39.1M; pipeline advances in SYNGAP1 and UCD programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.6M for Q2 2025, flat vs Q2 2024; R&D expenses $10.3M, G&A $4.2M.","Cash, cash equivalents and marketable securities $39.1M as of June 30, 2025, down from $49.3M on March 31, 2025.","SYNGAP1 program: translational data presented at ASGCT; GLP tox studies start Q3 2025; potential Phase 1/2 trial in H2 2026.","CMP-CPS-001 (UCD): completed dosing in MAD cohort 3; safety and biomarker data from SAD and MAD cohorts expected Q4 2025."],"consensus_eps_estimate":-0.6854,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":2355000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158755,"accession_number":"0001736730-25-000043","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CAMP4 Therapeutics annual meeting elects four Class I directors, ratifies EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["James Boylan elected with 15,802,709 votes for, 900,961 against, 6,002 abstain.","Amir Nashat, Andrew Schwab, and Douglas Williams each elected with >16 million votes for.","Ratification of Ernst & Young as auditor for FY2025: 17,900,199 for, 2,644 against, 6,002 abstain.","All proposals passed; meeting held June 11, 2025 as scheduled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158754,"accession_number":"0001736730-25-000041","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CAMP4 reports SYNGAP1 protein increase in NHPs and favorable Phase 1 safety data for UCD program at ASGCT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CMP-SYNGAP-01 restored SYNGAP1 protein to near-normal in haploinsufficient mice and rescued motor/learning defects.","In NHPs, biweekly intrathecal CMP-SYNGAP-01 achieved ~1.5-fold SYNGAP1 increase in relevant brain regions.","Phase 1 SAD data for CMP-CPS-001 in 48 healthy volunteers: well tolerated, no serious AEs, dose-dependent PK.","UCD preclinical: CMP-CPS-001 increased ureagenesis up to 40% in NHPs and reduced ammonia in mice.","Company plans to expand Phase 1 into OTC heterozygotes with reduced urea cycle function."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158753,"accession_number":"0001736730-25-000037","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CAMP4 Q1 net loss $12.4M; Phase 1 UCD data Q4 2025; SYNGAP1 candidate nominated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.4M for Q1 2025, flat YoY; cash, equivalents, and marketable securities $49.3M as of March 31, 2025.","Phase 1 trial of CMP-CPS-001 for Urea Cycle Disorders ongoing; safety, PK, PD data expected Q4 2025.","CTA submitted in Europe for Phase 1b clinical trial in female OTC heterozygotes.","Nominated development candidate CMP-SYNGAP-01 for SYNGAP1-related disorders; GLP tox studies expected 2025.","Milestone event achieved under Fulcrum license; eligible for $0.6M payment; potential up to $70M in milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":858000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177157,"accession_number":"0001736730-25-000021","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CAMP4 reports FY2024 net loss $51.8M; cash $64M, Phase 1 data expected Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $51.8M for FY2024 vs $49.3M in FY2023; R&D expenses $38.8M, G&A $14.9M.","Cash and equivalents $64.0M as of Dec 31, 2024; sufficient to fund into Q2 2026.","Phase 1 trial of CMP-CPS-001 for UCDs ongoing; SAD completed safely, MAD dosing in progress; safety, PK, PD data expected Q4 2025.","Phase 1b trial in female OTC heterozygotes expected Q2 2025 in Australia, Europe to follow.","Development candidate CMP-SYNGAP-01 nominated for SYNGAP1-related disorders; GLP tox studies planned 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177156,"accession_number":"0001736730-25-000004","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CAMP4 Therapeutics appoints two new directors, expands board to 12 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Douglas Williams, PhD and Murray Stewart, DM FRCP appointed as Class I and Class II directors, effective 3/17/25.","Board size increased from 10 to 12 members; Williams also appointed to Audit Committee.","Each new director granted option to purchase 17,787 shares under 2024 Equity Incentive Plan, vesting monthly over 3 years.","Standard indemnification agreements entered into; no prior transactions with company exceeding $120,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177155,"accession_number":"0001104659-25-001679","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Camp4 Therapeutics reports positive Phase 1 SAD safety data for CMP-CPS-001, enables MAD dose escalation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 SAD portion completed: 48 healthy volunteers, 32 received CMP-CPS-001; no serious adverse events, no maximum tolerated dose reached.","All treatment-emergent adverse events were Grade 1 or 2; most common: headache (6), nausea (4).","Safety Review Committee approved dose escalation and initiation of MAD Cohort 3.","Cash runway into Q2 2026; upcoming milestones: MAD data 2H'25, SYNGAP1 GLP tox studies in '25.","Corporate slide deck highlights RAP platform, pipeline, and strategic collaboration; IPO completed October 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193937,"accession_number":"0001104659-24-121533","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CAMP4 reports Q3 net loss $13.5M, completes IPO raising $82.1M, and signs BioMarin collaboration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 net loss $13.5M vs $11.7M in prior year; R&D $9.7M, G&A $3.8M.","Completed IPO in Oct 2024: 6.82M shares at $11.00, gross proceeds $82.1M (including partial underwriter option).","Entered strategic research collaboration with BioMarin valued at over $370M in milestones and royalties.","Phase 1 SAD portion completed; safety data expected Q1 2025, MAD biomarker data in H2 2025.","Cash $2.5M as of Sep 30, 2024; pro forma with IPO proceeds well-positioned to support development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193936,"accession_number":"0001104659-24-108583","cik":1736730,"company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"CAMP4 Therapeutics adopts post-IPO charter authorizing 175M common shares and eliminating written consent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fifth amended charter effective Oct 15, 2024; authorizes 175M shares of common stock and 25M shares of undesignated preferred stock.","Eliminates all references to previously existing series of preferred stock and removes stockholder ability to act by written consent.","Amended bylaws establish procedures for stockholder proposals and director nominations, and modify officer/director indemnification provisions.","Charter and bylaw changes were approved by board and stockholders prior to IPO consummation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":228213894.13182893,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}